The incidences of fungal infections have greatly increased over the past few years, particularly in humid and industrialized areas. The severity of such infections ranges from being asymptomatic-mild to potentially life-threatening systemic infections. There are limited classes of drugs that are approved for the treatment of such infections like polyenes, azoles, and echinocandins. Some fungi have developed resistance to these drugs. Therefore, to counter drug resistance, intensive large scale studies on novel targeting strategies and formulations are being conducted, which have gained impetus lately. Conventional formulations have limitations such as higher doses, frequent dosing, and several side effects. Such limiting factors have paved the path for the emergence of nanotechnology and its applications. This further gave formulation scientists the possibility of encapsulating the existing potential drug moieties into nanocarriers, which when loaded into gels or creams provided prolonged release and improved permeation, thus giving on-target effect. This review thus discusses the newer targeting strategies and the role of nanocarriers that could be administered topically for the treatment of various fungal infections. Furthermore, this approach opens newer avenues for continued and sustained research in pharmaceuticals with much more effective outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/dth.13905 | DOI Listing |
Infect Drug Resist
January 2025
Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Objective: To evaluate the diagnostic performance and clinical impact of targeted next-generation sequencing (tNGS) in patients with suspected lower respiratory tract infections.
Methods: Following propensity score matching, we compared the diagnostic performances of tNGS and metagenomic next-generation sequencing (mNGS). Furthermore, the diagnostic performance of tNGS was compared with that of culture, and its clinical impact was assessed.
Cureus
December 2024
Nephrology, Hospital Regional Hans Dieter Schmidt, Joinville, BRA.
Fungal peritonitis is an uncommon but serious complication that can occur in patients undergoing peritoneal dialysis. It represents a small percentage of all peritonitis cases in these patients. Its diagnosis can be challenging due to the slow growth of fungi and frequent negative culture results.
View Article and Find Full Text PDFOxf Med Case Reports
January 2025
Infection Control Department, An-Najah National University Hospital, Nablus 44839, West Bank, Palestine.
Background: may cause fatal infections in immunocompromised patients. This is the first case report of invasive infection at an academic-tertiary care center in Palestine.
Case Presentation: We report a 36-year-old woman who presented with fever and severe neutropenia and was found to have AML/Non M3.
J Biol Methods
October 2024
Department of Biochemistry, Sismanogleio Hospital, Athens 15126, Greece.
Background: Nanotechnology has emerged as a promising field for the diagnosis, monitoring, and treatment of respiratory tract infections (RTIs). By leveraging the unique properties of nanoscale delivery systems, nanotechnology can significantly enhance the selectivity and efficacy of antimicrobials, thereby reducing off-target effects.
Objective: This review explores the development and application of targeted nanosystems in combating viral, bacterial, and fungal RTIs.
Mycoses
January 2025
Laboratorio de Micología y Diagnóstico Molecular-Cátedra de Parasitología y Micología-Bioquímica, Universidad Nacional del Litoral, Santa Fe, Argentina.
Background: Access to fungal disease diagnosis is crucial for reducing mortality, yet it varies widely across Argentina, especially outside Buenos Aires. In regions like Santa Fe and Paraná, where most healthcare facilities are under 150 beds, maintaining specialised mycology labs is challenging.
Objectives: This work describes the establishment and first-year results of a centralised Fungal Disease Response Centre (FDRC) and referral network serving this region, covering approximately 1 million inhabitants.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!